Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $9.75 Average PT from Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $8.80.

INO has been the subject of a number of recent research reports. HC Wainwright reissued a “neutral” rating and issued a $3.00 price objective on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. Piper Sandler assumed coverage on shares of Inovio Pharmaceuticals in a report on Wednesday. They set an “overweight” rating and a $5.00 price objective for the company. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 27th. Oppenheimer dropped their price objective on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, May 14th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 price objective on shares of Inovio Pharmaceuticals in a report on Wednesday, May 14th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Nomura Holdings Inc. acquired a new stake in Inovio Pharmaceuticals during the first quarter worth $28,000. Alpine Global Management LLC bought a new stake in Inovio Pharmaceuticals in the 4th quarter valued at $31,000. Freedom Investment Management Inc. bought a new stake in Inovio Pharmaceuticals in the 1st quarter valued at $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares during the period. Finally, Bank of Montreal Can bought a new position in Inovio Pharmaceuticals during the 4th quarter worth $43,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Stock Down 2.2%

Shares of INO stock opened at $1.36 on Wednesday. The company has a 50 day moving average of $1.93 and a 200-day moving average of $1.93. Inovio Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $12.33. The firm has a market cap of $49.87 million, a P/E ratio of -0.43 and a beta of 1.31.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.23. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.01 million. As a group, equities analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.